These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33755393)

  • 1. An Integrated Clinical and Genetic Prediction Model for Tacrolimus Levels in Pediatric Solid Organ Transplant Recipients.
    Min S; Papaz T; Lambert AN; Allen U; Birk P; Blydt-Hansen T; Foster BJ; Grasemann H; Hamiwka L; Litalien C; Ng V; Berka N; Campbell P; Daniel C; Saw CL; Tinckam K; Urschel S; Van Driest SL; Parekh R; Mital S
    Transplantation; 2022 Mar; 106(3):597-606. PubMed ID: 33755393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients.
    Pasternak AL; Park JM; Pai MP
    Ther Drug Monit; 2023 Feb; 45(1):95-101. PubMed ID: 36624576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.
    Min S; Papaz T; Lafreniere-Roula M; Nalli N; Grasemann H; Schwartz SM; Kamath BM; Ng V; Parekh RS; Manlhiot C; Mital S
    Pediatr Transplant; 2018 Nov; 22(7):e13285. PubMed ID: 30178515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
    Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
    Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles.
    Oetting WS; Schladt DP; Guan W; Miller MB; Remmel RP; Dorr C; Sanghavi K; Mannon RB; Herrera B; Matas AJ; Salomon DR; Kwok PY; Keating BJ; Israni AK; Jacobson PA;
    Am J Transplant; 2016 Feb; 16(2):574-82. PubMed ID: 26485092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients.
    Wang P; Mao Y; Razo J; Zhou X; Wong ST; Patel S; Elliott E; Shea E; Wu AH; Gaber AO
    Pharmacogenomics; 2010 Oct; 11(10):1389-402. PubMed ID: 21047202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
    Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
    Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y; Kong Y; Hou X; Liu H; Fu Q; Jiao Z; Peng H; Wei X
    J Clin Pharm Ther; 2021 Aug; 46(4):1117-1128. PubMed ID: 33768546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients.
    Birdwell KA; Grady B; Choi L; Xu H; Bian A; Denny JC; Jiang M; Vranic G; Basford M; Cowan JD; Richardson DM; Robinson MP; Ikizler TA; Ritchie MD; Stein CM; Haas DW
    Pharmacogenet Genomics; 2012 Jan; 22(1):32-42. PubMed ID: 22108237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.
    Jacobson PA; Schladt D; Israni A; Oetting WS; Lin YC; Leduc R; Guan W; Lamba V; Matas AJ;
    Transplantation; 2012 Mar; 93(6):624-31. PubMed ID: 22334041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial.
    Billing H; Höcker B; Fichtner A; van Damme-Lombaerts R; Friman S; Jaray J; Vondrak K; Sarvary E; Dello Strologo L; Oellerich M; von Ahsen N; Tönshoff B
    Ther Drug Monit; 2017 Feb; 39(1):21-28. PubMed ID: 28030534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.
    Madsen MJ; Bergmann TK; Brøsen K; Thiesson HC
    Drugs R D; 2017 Jun; 17(2):279-286. PubMed ID: 28229376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients.
    Calabrese DR; Florez R; Dewey K; Hui C; Torgerson D; Chong T; Faust H; Rajalingam R; Hays SR; Golden JA; Kukreja J; Singer JP; Greenland JR
    Clin Transplant; 2018 Aug; 32(8):e13332. PubMed ID: 29920787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.
    Andreu F; Colom H; Elens L; van Gelder T; van Schaik RHN; Hesselink DA; Bestard O; Torras J; Cruzado JM; Grinyó JM; Lloberas N
    Clin Pharmacokinet; 2017 Aug; 56(8):963-975. PubMed ID: 28050888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
    Gijsen V; Mital S; van Schaik RH; Soldin OP; Soldin SJ; van der Heiden IP; Nulman I; Koren G; de Wildt SN
    J Heart Lung Transplant; 2011 Dec; 30(12):1352-9. PubMed ID: 21930396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.